Cugene is a preclinical-stage biotechnology company founded by a team of pharmaceutical veterans with proven drug development records that is advancing an armamentarium of precision immunotherapies with compelling, clinically validated targets for large market autoimmune and oncology indications. Cugene's lead program in its Autoimmune Franchise is a Treg-selective IL-2 variant with potentially best-in-class (1) Treg activity and selectivity, (2) safety, and (3) manufacturability; Cugene's lead program in Oncology is an IL-15 agonist that has demonstrated superior PK/PD and efficacy to NantCell's N-803 in preclinical studies. Each of Cugene's programs possesses not only best-in-class potential, but also high approvability.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
(1) CUG252, a Treg-selective IL-2 variant; (2) CUG105, a long-acting IL-15 agonist
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):